公开(公告)号：US20140236293A1

公开(公告)日：2014-08-21

申请号：US14265071

申请日：2014-04-29

Applicant: Mati Therapeutics Inc.

Inventor： Eugene De Juan, JR. ,  Stephen Boyd ,  Cary Reich ,  Alan Rapacki ,  Hanson S. Gifford ,  Mark Deem

IPC: A61F9/00

CPC classification number: A61K9/0051 ,  A61F9/0017 ,  A61F9/0026 ,  A61F9/00772 ,  A61F9/00781 ,  A61F2220/0008 ,  A61F2250/0067 ,  A61F2250/0087 ,  A61K9/00 ,  A61K9/0017 ,  A61K9/06 ,  A61K31/215 ,  A61K31/216 ,  A61K31/55 ,  A61K31/557 ,  A61K31/5575 ,  A61K31/573 ,  A61K47/34 ,  A61L31/16

Abstract: An implant for insertion through a punctum and into a canalicular lumen of a patient. The implant includes a matrix of material, a therapeutic agent dispersed in the matrix of material, a sheath disposed over a portion of the matrix of material and configured to inhibit the therapeutic agent from being released from the matrix of material into the canalicular lumen and to allow the therapeutic agent to be released from a surface of the matrix of material to a tear film, and a retention structure configured to retain the implant within the canalicular lumen.

Abstract translation: 用于插入通过泪点并进入患者的小管腔的植入物。 植入物包括材料基质，分散在材料基质中的治疗剂，鞘层，其设置在材料基质的一部分上并且被配置为抑制治疗剂从材料基质释放到小管腔内，并且 允许治疗剂从材料基质的表面释放到泪膜，以及构造成将植入物保持在小管腔内的保留结构。

公开(公告)号：US20140186420A1

公开(公告)日：2014-07-03

申请号：US14098317

申请日：2013-12-05

Applicant: Mati Therapeutics, Inc.

Inventor： Deepank Utkhede ,  Robert W. Shimizu ,  Rachna Jain ,  Stephen Boyd ,  Hanson S. Gifford ,  Eugene De Juan, JR. ,  Cary J. Reich

IPC: A61K9/00 ,  A61K31/5575

CPC classification number: A61K9/0051 ,  A61F9/0017 ,  A61F9/00772 ,  A61F2230/0069 ,  A61F2250/0067 ,  A61K31/5575 ,  A61K47/34 ,  A61L27/54 ,  A61L2300/41 ,  A61L2300/602 ,  A61L2300/802 ,  Y02A50/395

Abstract: A solid drug core insert can be manufactured by injecting a liquid mixture comprising a therapeutic agent and a matrix precursor into a sheath body. The injection can be conducted at subambient temperatures. The mixture is cured to form a solid drug-matrix core. The therapeutic agent can be a liquid at about room temperature that forms a dispersion of droplets in the matrix material. A surface of the solid drug core is exposed, for example by cutting the tube, and the exposed surface of the solid drug core releases therapeutic quantities of the therapeutic agent when implanted into the patient. In some embodiments, the insert body inhibits release of the therapeutic agent, for example with a material substantially impermeable to the therapeutic agent, such that the therapeutic quantities are released through the exposed surface, thereby avoiding release of the therapeutic agent to non-target tissues.

Abstract translation: 可以通过将包含治疗剂和基质前体的液体混合物注入鞘体来制造固体药物核心插入物。 注射可以在低于环境温度下进行。 将混合物固化以形成固体药物基质核心。 治疗剂可以是在约室温下的液体，其形成液滴在基质材料中的分散体。 固体药物核心的表面例如通过切割管而暴露，并且固体药物核心的暴露表面在植入患者体内释放治疗剂量。 在一些实施方案中，插入体抑制治疗剂的释放，例如具有对治疗剂基本上不可渗透的材料，使得治疗量通过暴露表面释放，从而避免将治疗剂释放到非靶组织 。

公开(公告)号：US20140161863A1

公开(公告)日：2014-06-12

申请号：US14180592

申请日：2014-02-14

Applicant: Mati Therapeutics, Inc.

Inventor： Eugene De Juan, JR. ,  Stephen Boyd ,  Hanson S. Gifford, III ,  Mark Deem ,  Cary J. Reich

IPC: A61K9/00 ,  A61K31/216

CPC classification number: A61K9/0051 ,  A61F9/0017 ,  A61F9/0026 ,  A61F9/00772 ,  A61F9/00781 ,  A61F2220/0008 ,  A61F2250/0067 ,  A61F2250/0087 ,  A61K9/00 ,  A61K9/0017 ,  A61K9/06 ,  A61K31/215 ,  A61K31/216 ,  A61K31/55 ,  A61K31/557 ,  A61K31/5575 ,  A61K31/573 ,  A61K47/34 ,  A61L31/16

Abstract: A drug insert is configured for use with an implant. The implant is configured for insertion into a lacrimal canaliculus. The drug insert includes a drug core comprising a therapeutic agent and a polymer; and a sheath body comprising material substantially impermeable to the therapeutic agent, wherein the drug core is positioned within the sheath body. The sheath body is configured to provide an exposed end of the drug core that releases therapeutic agent to an eye when the drug insert is disposed within the implant and the implant is positioned in the lacrimal canaliculus. A distal end of the drug core is sealed with a medical-grade adhesive.

Abstract translation: 药物插入物配置成与植入物一起使用。 植入物构造成用于插入泪小管。 药物插入物包括药物核心，其包含治疗剂和聚合物; 以及鞘体，其包含基本上不可渗透到治疗剂的材料，其中所述药物核心位于所述鞘体内。 护套主体构造成当药物插入物设置在植入物内并且植入物位于泪小管中时，提供药物核心的暴露端​​，其将治疗剂释放到眼睛。 药物核心的远端用医用级粘合剂密封。